Biotech stocks surge on clinical-trial developments at GI Innovation and D&D; ASCO and liver conference in focus

GI Innovation 5 after abstracts submitted to ASCO in 23 its share price rose by about . The company said it reported an objective response rate (ORR) of 40. The news drew investors’ attention.

D&D Pharmatech was reported to have risen by 14 amid expectations for clinical results related to the European liver conference. The company said it is preparing liver-related clinical results. The presentation schedule and timing of the detailed data release are drawing attention.

Lunit will present at ASCO 2026 results from research using AI for biomarker analysis. The company said it submitted results from AI-based tissue analysis to the conference. The presentation is bringing research collaboration and the potential for clinical application into focus.

Ingenia Therapeutics has received approval to proceed with a preliminary review for a U.S. listing. The company said it plans to move forward with the listing process. This is the next step in its plan to enter the U.S. market.

Solux announced that it is considering changing its name to Ariwon and stepping up its transition to a biotech platform. The company said it plans to shift its business structure to focus on the platform. It plans to disclose further details about the transition schedule and business model.

The series of announcements shows that share-price movements occurred in line with each company’s clinical and conference schedules and listing procedures. Investors should check the original announcements and detailed data to be released later. They should also monitor further disclosure schedules.